These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22732882)

  • 21. Predictive QSAR modeling of HIV reverse transcriptase inhibitor TIBO derivatives.
    Mandal AS; Roy K
    Eur J Med Chem; 2009 Apr; 44(4):1509-24. PubMed ID: 18760864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
    Auwerx J; Van Nieuwenhove J; Rodríguez-Barrios F; de Castro S; Velázquez S; Ceccherini-Silberstein F; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
    FEBS Lett; 2005 Apr; 579(11):2294-300. PubMed ID: 15848161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Combined Approach of Pharmacophore Modeling, QSAR Study, Molecular Docking and In silico ADME/Tox Prediction of 4-Arylthio & 4-Aryloxy-3- Iodopyridine-2(1H)-one Analogs to Identify Potential Reverse Transcriptase Inhibitor: Anti-HIV Agents.
    Panigrahi D; Mishra A; Sahu SK; Azam MA; Vyshaag CM
    Med Chem; 2022; 18(1):51-87. PubMed ID: 33319692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2D and 3D QSAR studies of diarylpyrimidine HIV-1 reverse transcriptase inhibitors.
    Rebehmed J; Barbault F; Teixeira C; Maurel F
    J Comput Aided Mol Des; 2008 Nov; 22(11):831-41. PubMed ID: 18506577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-Alkyl-2-alkylamino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new series of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors belonging to the DABO family.
    Mai A; Artico M; Ragno R; Sbardella G; Massa S; Musiu C; Mura M; Marturana F; Cadeddu A; Maga G; La Colla P
    Bioorg Med Chem; 2005 Mar; 13(6):2065-77. PubMed ID: 15727860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase.
    Rodríguez-Barrios F; Pérez C; Lobatón E; Velázquez S; Chamorro C; San-Félix A; Pérez-Pérez MJ; Camarasa MJ; Pelemans H; Balzarini J; Gago F
    J Med Chem; 2001 Jun; 44(12):1853-65. PubMed ID: 11384232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in QSAR studies of HIV-1 reverse transcriptase inhibitors.
    Gupta SP
    Prog Drug Res; 2002; 58():223-64. PubMed ID: 12079201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors.
    Ribone SR; Leen V; Madrid M; Dehaen W; Daelemans D; Pannecouque C; Briñón MC
    Eur J Med Chem; 2012 Dec; 58():485-92. PubMed ID: 23159806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting anti-HIV activity of 1,3,4-thiazolidinone derivatives: 3D-QSAR approach.
    Ravichandran V; Prashantha Kumar BR; Sankar S; Agrawal RK
    Eur J Med Chem; 2009 Mar; 44(3):1180-7. PubMed ID: 18687505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hologram quantitative structure-activity relationships investigations of non-nucleoside reverse transcriptase inhibitors.
    Pungpo P; Hannongbua S; Wolschann P
    Curr Med Chem; 2003 Sep; 10(17):1661-77. PubMed ID: 12871115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How good are ensembles in improving QSAR models? The case with eCoRIA.
    Khedkar VM; Joseph J; Pissurlenkar R; Saran A; Coutinho EC
    J Biomol Struct Dyn; 2015; 33(4):749-69. PubMed ID: 24754910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Docking-based 3D-QSAR analyses of pyrazole derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Cichero E; Fossa P
    J Mol Model; 2012 Apr; 18(4):1573-82. PubMed ID: 21805124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of novel S-N
    Ling X; Hao QQ; Huang WJ; Pannecouque C; De Clercq E; Wang S; Chen FE
    Eur J Med Chem; 2023 Feb; 247():115042. PubMed ID: 36577220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Designing hypothesis of substituted benzoxazinones as HIV-1 reverse transcriptase inhibitors: QSAR approach.
    Veerasamy R; Subramaniam DK; Chean OC; Ying NM
    J Enzyme Inhib Med Chem; 2012 Oct; 27(5):693-707. PubMed ID: 21961709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemical structure and correlation analysis of HIV-1 NNRT and NRT inhibitors and database-curated, published inhibition constants with chemical structure in diverse datasets.
    Viira B; García-Sosa AT; Maran U
    J Mol Graph Model; 2017 Sep; 76():205-223. PubMed ID: 28738270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CoMFA 3D-QSAR analysis of HIV-1 RT nonnucleoside inhibitors, TIBO derivatives based on docking conformation and alignment.
    Zhou Z; Madura JD
    J Chem Inf Comput Sci; 2004; 44(6):2167-78. PubMed ID: 15554687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Hu R; Barbault F; Delamar M; Zhang R
    Bioorg Med Chem; 2009 Mar; 17(6):2400-9. PubMed ID: 19250835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-activity relationship studies on potential non-nucleoside DABO-like inhibitors of HIV-1 reverse transcriptase.
    Costi R; Di Santo R; Artico M; Massa S; Lavecchia A; Marceddu T; Sanna L; La Colla P; Marongiu ME
    Antivir Chem Chemother; 2000 Mar; 11(2):117-33. PubMed ID: 10819436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors.
    Balzarini J; Auwerx J; Rodríguez-Barrios F; Chedad A; Farkas V; Ceccherini-Silberstein F; García-Aparicio C; Velázquez S; De Clercq E; Perno CF; Camarasa MJ; Gago F
    Mol Pharmacol; 2005 Jul; 68(1):49-60. PubMed ID: 15833734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
    Ragno R; Artico M; De Martino G; La Regina G; Coluccia A; Di Pasquali A; Silvestri R
    J Med Chem; 2005 Jan; 48(1):213-23. PubMed ID: 15634015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.